On 30-31 October 2019, the consortium came together in Granada, Spain, to officially kick off the 3TR project activities.
https://www.3tr-imi.eu/
The LBAI laboratory "B cells and Autoimmunity" (UBO / Inserm), member of LabEx IGO, will participate in the 3TR project, the largest immunology project ever funded in the framework of European projects by "Innovative Medicine Initiative 2" (IMI2). It aims to improve the management of patients who do not respond to treatment in seven autoimmune, allergic or inflammatory diseases: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (including ulcerative colitis and Crohn's disease), asthma and chronic obstructive pulmonary disease.

With the 3TR project, researchers will have access to an unprecedented amount of clinical data and biological samples from more than 50,000 patients in 50 clinical trials. The goal of the project is to combine and integrate the analysis of the seven diseases to identify the relationships between the multi-omic and microbiome profiles in blood cells and tissues. For this, scenarios will be established according to the disease evolution trajectories.

The 3TR project brings together renowned interdisciplinary experts from 69 academic and industrial institutions from 15 European countries. It is funded by more than € 80 million over the next 7 years by IMI2, a joint venture of the European Union and the European Federation of Pharmaceutical Industries (EFPIA).

LBAI is one of the three French academic representatives of the consortium and the only one involved in the analysis of the generated data. 3TR is the fourth European fund financing obtained by LBAI in 5 years.

Visit the 3TR project website: www.3tr-imi.eu
View the presentation video